Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: Cohort study

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Hippisley Cox, Julia ^a   Coupland, Carol ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; AGE; AGED; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; BODY MASS; CALIBRATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DEPRIVATION SCORE; DIABETES MELLITUS; ENGLAND; ETHNICITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENERAL PRACTICE; HAZARD RATIO; HUMAN; INTESTINE CANCER; LIVER DISEASE; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; PERCEPTION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SMOKING; THROMBOCYTE COUNT; VALIDATION PROCESS; VERY ELDERLY; ADULT; ADVERSE EFFECTS; COLORECTAL TUMOR; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; COMORBIDITY; DATABASES, FACTUAL; DIABETES MELLITUS; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 85020864284     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2497     Document Type: Article

References (51)

1. Howlader N, Mariotto AB, Woloshin S, Schwartz LM. Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death. J Natl Cancer Inst Monogr 2014;2014:255-64. doi:10.1093/jncimonographs/lgu022.
2. Cancer Research UK. Bowel Cancer Survival Statistics London 2015 http://www.cancerresearchuk.org/health-professional/cancerstatistics/ statistics-by-cancer-type/bowel-cancer/survival accessed 03.12.2015 2015.
3. Gill S, Loprinzi C, Kennecke H, et al. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer 2011;117:4155-65. doi:10.1002/cncr.26003.
4. Surveillance Epidemiology and End Results tumour Registry. Adjuvant! Online 2016 https://adjuvantonline.com/ accessed 07/12/2016 2016.
5. Renfro LA, Grothey A, Xue Y, et al. Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst 2014;106:dju333. doi:10.1093/jnci/dju333.
6. Weiser MR, G'nen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol 2011;29:4796-802. doi:10.1200/ JCO.2011.36.5080.
7. Reljic T, Kumar A, Klocksieben FA, Djulbegovic B. Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open 2017;7:e014661. doi:10.1136/ bmjopen-2016-014661.
8. Wise PH. Cancer drugs, survival, and ethics. BMJ 2016;355:i5792. doi:10.1136/bmj.i5792.
9. Hancock K, Clayton JM, Parker SM, et al. Truth-telling in discussing prognosis in advanced life-limiting illnesses: a systematic review. Palliat Med 2007;21:507-17. doi:10.1177/0269216307080823.
10. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 2009;27:5938-43. doi:10.1200/JCO.2009.23.1860.
11. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
12. Hippisley-Cox J, Coupland C. Identifying patients with suspected colorectal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e29-37. doi:10.3399/ bjgp12X616346.
13. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open 2015;5:e007825. doi:10.1136/bmjopen-2015-007825.
14. Coleman MP, Forman D, Bryant H, et al. ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127-38. doi:10.1016/S0140-6736(10)62231-3.
15. McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer 2015;112(Suppl 1):S108-15. doi:10.1038/bjc.2015.49.
16. Maringe C, Walters S, Rachet B, et al. ICBP Module 1 Working Group. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol 2013;52:919-32. doi:10.3109/02841 86X.2013.764008.
17. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM classification of malignant tumours.Wiley-Blackwell, 2009.
18. Cai H, Zhang G, Wang Z, Luo Z, Zhou X. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis. PLoS One 2015;10:e0126944. doi:10.1371/ journal.pone.0126944.
19. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802. doi:10.1056/NEJMoa1201735.
20. Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012;106:1564-70. doi:10.1038/bjc.2012.101.
21. Bains SJ, Mahic M, Myklebust T, et al. Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study. J Clin Oncol 2016;34:2501-8. doi:10.1200/JCO.2015.65.3519.
22. Hippisley-Cox J, Coupland C. Predicting risk of emergency admission to hospital using primary care data: derivation and validation of QAdmissions score. BMJ Open 2013;3:e003482. doi:10.1136/ bmjopen-2013-003482.
23. Townsend P, Davidson N. The Black report.Penguin, 1982.
24. Steyerberg EW, van Veen M. Imputation is beneficial for handling missing data in predictive models. J Clin Epidemiol 2007;60:979. doi:10.1016/j.jclinepi.2007.03.003.
25. Moons KGM, Donders RART, Stijnen T, Harrell FE Jr. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 2006;59:1092-101. doi:10.1016/j.jclinepi.2006.01.009.
26. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002;7:147-77. doi:10.1037/1082-989X.7.2.147.
27. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009;28:1982-98.
28. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-74. doi:10.1093/ije/28.5.964.
29. Rubin DB. Multiple Imputation for Non-response in Surveys.John Wiley, 1987doi:10.1002/9780470316696.
30. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data.John Wiley, 2002doi:10.1002/9781118032985.
31. Hieke S, Kleber M, Konig C, Engelhardt M, Schumacher M. Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. Clin Cancer Res 2015;21:1530-6. doi:10.1158/1078-0432.CCR-14-2154.
32. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363-71. doi: 10.1161/ CIRCOUTCOMES.110.957951.
33. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;26:3913-5. doi:10.1200/ JCO.2008.16.1000.
34. Royston P. Explained variation for survival models. Stata J 2006;6:1-14.
35. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004;23:723-48. doi:10.1002/sim.1621.
36. Harrell FE Jr, , Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. doi:10.1002/ (SICI)1097-0258(19960229)15:4361::AID-SIM1683.0.CO;2-4.
37. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004;4:103-12.
38. Allemani C, Weir HK, Carreira H, et al. CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010. doi:10.1016/S0140-6736(14)62038-9.
39. Yu XQ, Baade PD, O'Connell DL. Conditional survival of cancer patients: an Australian perspective. BMC Cancer 2012;12:460. doi:10.1186/1471-2407-12-460.
40. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21:128-38. doi:10.1097/EDE.0b013e3181c30fb2.
41. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ 2016;352:i6. doi:10.1136/bmj.i6.
42. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-74. doi:10.1177/0272989X06295361.
43. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162:55-63. doi:10.7326/M14-0697.
44. Hippisley-Cox J, Coupland C. Protocol for development and validation of risk prediction equations to estimate absolute and conditional survival in patients with cancer, 2016. http://eprints.nottingham. ac.uk/33946/
45. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004;40:2307-16.
46. Fuller CD, Wang SJ, Thomas CR Jr, , Hoffman HT, Weber RS, Rosenthal DI. Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer 2007;109:1331-43. doi:10.1002/cncr.22563.
47. Sanoff HK, Carpenter WR, Stormer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012;30:2624-34. doi:10.1200/JCO.2011.41.1140.
48. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7. doi:10.1056/NEJMoa010957.
49. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010;341:c6624. doi:10.1136/bmj.c6624.
50. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 2004;(21):5-14.
51. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 2010;39:598-610. doi:10.1093/ije/dyp392.